Partnering with Yisheng

Press Releases

Yisheng Biopharma Receives GMP Certification from China NMPA for Production of Lyophilized Rabies Vaccine for Preventive Use

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that its new rabies vaccine production facility has received a Pharmaceutical GMP Certificate from the China National Medical Products Administration (NMPA) for production of its Yisheng Junan™ product, the first lyophilized rabiesRead More

Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that it has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China to initiate a clinical trial of YS-ON-001, a first-in-class immuno-oncology product for the treatment of advanced solidRead More

Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced today that an abstract has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019Read More

Yisheng Biopharma Announces Clearance from China FDA to Proceed with PIKA Rabies Vaccine Clinical Study

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immune modulator biotherapeutics and vaccines, today announced that the China Food and Drug Administration (CFDA) has provided clearance to proceed with a clinical trial of its PIKA® rabies vaccine. The PIKA rabies vaccine has the potential to become aRead More

Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma businessRead More

The US FDA Granted Orphan Drug Designation to Yisheng Biopharma’s Biological Product for Pancreatic Cancer Treatment

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. To date the US FDARead More

Yisheng Biopharma Announces New Breakthrough Results on YS-ON-001 in Multiple Solid Tumor Experiments

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced that its first-in-class immuno-oncology product candidate, YS-ON-001, demonstrated strong anti-tumor efficacy as a standalone therapy and synergistic effect when combined with antibody blocking programmed death receptor-1 (PD-1) in multiple animal modelsRead More

Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced that the first patient with advanced stage cancer was enrolled in a Phase I immuno-oncology trial of YS-ON-001, a lead product candidate for the treatment of advanced solid tumors. YS-ON-001 isRead More

Yisheng Biopharma to Present at BioPharma Asia Convention 2017 in Singapore

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the company will present at annual BioPharma Asia Convention 2017 at Suntec Convention Center, Singapore. The presentation is scheduled for 12:40 PM local time on March 22, 2017. The managementRead More

US FDA Grants Orphan Drug Designation to Yisheng Biopharma’s PIKA Rabies Vaccine

Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its lead vaccine candidate, PIKA rabies vaccine, which is an innovative rabies vaccine independently developed by YishengRead More